The full results of the third episode have not been submitted

kēāvasin ānṟibēāḍiyuṭe parīkṣaṇātmaka prayēāgattinṟe mūnnāṁ ghaṭṭattinṟe pūrṇa phalaṅṅaḷ manuṣyarkk samarppikkunnatil parājayappeṭṭatinṟe pēril yu’es phuḍ ānḍ ḍrag aḍminisṭrēṣan (ephḍi’e) intyan bayēāṭek kampaniyuṭe kliyaṟans tālkkālikamāyi nirttivaccu. ī sāhacaryattil, kēāvāsin vāksin upayēāgicc amērikkayilēkk pēākunna intyakkārkk ā rājyatt oru putiya vāksin eṭukkēṇṭi vannēkkāṁ. vāksinukaḷuṭe mūnnāṁ ghaṭṭa phalaṅṅaḷ ētānuṁ āḻcakaḷkkuḷḷil puṟattuviṭumenn kēndraṁ avakāśappeṭunnu. itinṟe aṭisthānattil haidarābādil ninnuḷḷa kampanikk amērikkayiluṁ kliyaṟans labhikkuṁ. mārcc vare kampani pariśēādhanā phalaṅṅaḷ samarppiccirunnu. ennāl mey māsattil ephḍi‌e putiya niyamaṅṅaḷ avatarippiccu, ini mutal ēteṅkiluṁ vāksin manuṣya śarīrattil parīkṣaṇātmaka āplikkēṣanṟe mūnnāṁ ghaṭṭameṅkiluṁ pūrṇṇa phalaṅṅaḷ samarppiccāl mātramē oḻivākkappeṭukayuḷḷū. muḻuvan phalaṅṅaḷuṁ jūlai ādyaṁ labhikkumenn kēāvāsin utpādippikkunna kampani. atinṟe aṭisthānattil vīṇṭuṁ apēkṣikkuṁ. amērikkayil kēāvāsin ulpādippikkunnatinuṁ vitaraṇaṁ ceyyunnatinumāyi akvājen enna kampani intya bayēāṭekkumāyi dhāraṇayiletti. ā ējansi vaḻi, intya bayēāṭek avaruṭe vāksinukaḷ amērikkayil aṭiyantira aṭisthānattil upayēāgikkān anumati tēṭi. innale parīkṣaṇātmaka āplikkēṣanāyi śēkharicca vivaraṅṅaḷ apūrṇṇavuṁ bhāgikavumāṇenn apēkṣa nirasiccu. niravadhi ṟippēārṭṭukaḷ samarppikkukayuṁ phalaṅṅaḷ pēāsiṟṟīv āṇeṅkil, bayēāḷajiks laisans āplikkēṣan (bi‌el‌e) alleṅkil ā rājyatt marunninṟe upayēāgaṁ pūrṇṇamāyuṁ oḻivākkappeṭuṁ. mūnnāṁ ṟa round ṇṭ kēāvāsin ṭesṟṟinṟe phalaṅṅaḷ pūrṇṇa anumatikkāyi apēkṣikkunnatināyi varuṁ divasaṅṅaḷil ephḍi‌eykk samarppikkumenn akvājan prastāvanayil paṟaññu. itin kuṟacc samayameṭutteṅkiluṁ, kēāvāsin maṟumarunn amērikkayilēkk keāṇṭuvarān kampani tīrumāniccu. ārēāgya mantrālayattinṟe prativāra patrasam’mēḷanattil pēāḷisi kam’mīṣan aṅgaṁ (ārēāgyaṁ) binēād pēāḷ paṟaññu, cila śāstrīya caṭṭakkūṭukaḷ alleṅkil mārgganirddēśaṅṅaḷkkanusr̥tamāyi iḷav anuvadicciṭṭuṇṭeṅkiluṁ, ōrēā rājyattinuṁ vyatyasta vyavasthakaḷuṇṭ. kēāvāsin mūnnāmatte ḍēās nāl playstre’am ētānuṁ āḻcakaḷkkuḷḷil phalaṅṅaḷ puṟattuvarumenn pratīkṣikkunnu. ā aṭisthānattil niṅṅaḷ apēkṣikkukayāṇeṅkil, kliyaṟansinṟe praś‌namuṇṭākillenn pratīkṣikkāṁ. it intyayile rēāgapratirēādha pad’dhatiye bādhikkunnatin oru kāraṇavumilla. ” mūnnāṁ ghaṭṭattinṟe parīkṣaṇātmaka prayēāgattekkuṟiccuḷḷa paṭhanattinṟe phalaṅṅaḷ manuṣyaśarīrattil samarppikkunnatil parājayappeṭṭatin lēākārēāgya saṅghaṭana (ḍablyu’ecco) kēāvāsin ituvare anumati nalkiyiṭṭilla. atukeāṇṭāṇ āḷukaḷ intyayil ninn kēāvāsin ānṟibēāḍikaḷumāyi sadi aṟēbya, amērikka, briṭṭan tuṭaṅṅiya rājyaṅṅaḷilēkk pēākumpēāḷ, putiya eccyu aṅgīkaricca vāksin eṭukkān āvaśyappeṭunnat. jūlaiyile mūnnāṁ ghaṭṭa phalaṅṅaḷkk śēṣaṁ asvasthatakaḷ nīṅṅumenn intya bayēāṭek karutunnu.
Show more
2744 / 5000
Translation results
The U.S. Food and Drug Administration (FDA) has suspended the clearance of an Indian biotech company for failing to submit the full results of the third phase of the experimental application of the Kovacin antibody to humans. In this case, Indians going to the United States with the Kovacin vaccine may need to get a new vaccine in that country. The Center claims that the third phase results of the vaccine will be released in a few weeks. Based on this, the company from Hyderabad will get clearance in the US as well. The company had submitted the test results till March. But in May, the FDA introduced new rules that would no longer exclude any vaccine unless at least the third stage of experimental application in the human body had yielded full results.

Kovacin-producing company said full results will be available by early July. Will apply again on that basis. Aquagen has entered into an agreement with India Biotech to manufacture and distribute Kovacin in the United States. Through that agency, India Biotech sought permission to use their vaccines in the United States on an emergency basis. Yesterday

The application rejected that the information collected for the experimental application was incomplete and partial. If several reports are submitted and the results are positive, the Biology License Application (BLA) or the use of the drug in that country will be completely eliminated. Aquajan said in a statement that the results of the third round Kovacin test will be submitted to the FDA in the coming days to apply for full approval. Although this took some time, the company decided to bring Kovacin antidote to the United States.

At the weekly press conference of the Ministry of Health, Policy Commission member (Health) Binod Paul said that although exemptions are granted according to certain scientific frameworks or guidelines, each country has different conditions. Kovasin third dose

Four plystream
The results are expected in a few weeks. If you apply on that basis, you can expect no clearance problem. This has no reason to affect the immune system in India. ”

Kovacin has not yet been approved by the World Health Organization (WHO) for failing to submit the results of a study on the experimental application of phase III to the human body. That is why when people travel from India to countries like Saudi Arabia, USA and UK with Kovacin antibodies, they are asked to take the new HU approved vaccine. India Biotech expects the unrest to move after the third phase results in July.